NASDAQ:IMA ImageneBio (IMA) Stock Price, News & Analysis $5.01 -0.04 (-0.79%) Closing price 09/9/2026 03:59 PM EasternExtended Trading$5.07 +0.06 (+1.10%) As of 09/9/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About ImageneBio Stock (NASDAQ:IMA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ImageneBio alerts:Sign Up Key Stats Today's Range$4.86▼$5.2050-Day Range$4.85▼$6.1152-Week Range$3.94▼$9.22Volume20,938 shsAverage Volume11,107 shsMarket Capitalization$56.86 millionP/E RatioN/ADividend YieldN/APrice Target$29.00Consensus RatingHold Company Overview ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California. Read More ImageneBio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks41st Percentile Overall ScoreIMA MarketRank™: ImageneBio scored higher than 41% of companies evaluated by MarketBeat, and ranked 626th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingHold Consensus RatingImageneBio has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 1 strong buy rating, 1 buy rating, 1 hold rating, and 2 sell ratings.Upside PotentialImageneBio has a consensus price target of $29.00, representing about 478.8% upside from its current price of $5.01.Amount of Analyst CoverageImageneBio has only been the subject of 2 research reports in the past 90 days.Read more about ImageneBio's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for ImageneBio are expected to decrease in the coming year, from ($3.23) to ($3.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ImageneBio is -1.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ImageneBio is -1.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImageneBio has a P/B Ratio of 0.42. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.44% of the float of ImageneBio has been sold short.Short Interest Ratio / Days to CoverImageneBio has a short interest ratio ("days to cover") of 4.95.Change versus previous monthShort interest in ImageneBio has recently decreased by 87.18%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldImageneBio does not currently pay a dividend.Dividend GrowthImageneBio does not have a long track record of dividend growth. News and Social Media0.0 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for ImageneBio this week, compared to 2 articles on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, ImageneBio insiders have not sold or bought any company stock.Percentage Held by Insiders2.22% of the stock of ImageneBio is held by insiders.Percentage Held by Institutions75.00% of the stock of ImageneBio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ImageneBio's insider trading history. Receive IMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ImageneBio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IMA Stock News HeadlinesImageneBio to Participate in H.C. Wainwright 28th Annual Global Investment Conference in New YorkSeptember 8 at 4:50 PM | markets.businessinsider.comImageneBio to Participate in H.C. Wainwright 28th Annual Global Investment Conference in New YorkSeptember 8 at 4:30 PM | globenewswire.comDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concerns about government authority to freeze or seize private accounts. Greece raided pensions. Cyprus drained bank accounts. Poland seized retirement funds. Priority Gold has put together a free Wealth Defense Guide for Americans looking to move assets beyond potential government reach.September 10 at 1:00 AM | Priority Gold (Ad)ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 17, 2026 | markets.businessinsider.comImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 17, 2026 | globenewswire.comImageneBio Reports Second Quarter 2026 Financial ResultsAugust 5, 2026 | globenewswire.comImageneBio Strengthens Leadership with New CFO AppointmentJuly 23, 2026 | tipranks.comImageneBio Stock Short Interest Report | NASDAQ:IMA | BenzingaJuly 7, 2026 | benzinga.comSee More Headlines IMA Stock Analysis - Frequently Asked Questions How have IMA shares performed this year? ImageneBio's stock was trading at $6.90 at the start of the year. Since then, IMA stock has decreased by 27.4% and is now trading at $5.01. How were ImageneBio's earnings last quarter? ImageneBio, Inc. (NASDAQ:IMA) issued its quarterly earnings results on Wednesday, August, 5th. The company reported ($0.63) earnings per share for the quarter, topping analysts' consensus estimates of ($0.90) by $0.27. When did ImageneBio's stock split? ImageneBio shares reverse split on Monday, July 28th 2025.The 1-12 reverse split was announced on Friday, July 25th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 25th 2025. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. Who are ImageneBio's major shareholders? Top institutional shareholders of ImageneBio include Blue Owl Capital Holdings LP (8.62%), Cable Car Capital LP (7.34%), Trails Edge Capital Partners LP (2.48%) and BlackRock Inc. (1.27%). Insiders that own company stock include Otello Stampacchia and Joseph P Slattery. View institutional ownership trends. How do I buy shares of ImageneBio? Shares of IMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/05/2026Today9/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (34m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 IMA's financial health is in the Red zone, according to TradeSmith. IMA has been in this zone for over 34 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:IMA Previous SymbolNASDAQ:IMA CIK1835579 Webikenaoncology.com Phone857-273-8343FaxN/AEmployees70Year Founded2016Price Target and Rating Average Price Target for ImageneBio$29.00 High Price Target$30.00 Low Price Target$28.00 Potential Upside/Downside+478.8%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($4.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$45.35 million Net MarginsN/A Pretax Margin-5,712.38% Return on Equity-38.99% Return on Assets-34.84% Debt Debt-to-Equity RatioN/A Current Ratio21.47 Quick Ratio21.47 Sales & Book Value Annual Sales$800 thousand Price / Sales71.08 Cash FlowN/A Price / Cash FlowN/A Book Value$11.91 per share Price / Book0.42Miscellaneous Outstanding Shares11,350,000Free Float11,099,000Market Cap$56.86 million OptionableNot Optionable Beta0.70 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:IMA) was last updated on 9/10/2026 by MarketBeat.com Staff. From Our PartnersGold Explorer Sits Between Barrick’s Nevada GiantsBarrick Mining has spent decades building one of Nevada's richest gold districts, anchored by Fourmile, Goldru...Wall Street Logic | SponsoredAmerican retirees will miss THIS. Big Banks just moved in.Central banks spent nearly $130 billion on physical gold last year, on top of $145 billion the year before. Q1...Cedar Gold Group | SponsoredWashington Is Broke—Could YOUR Savings Be Next?The Department of Justice recently argued in court that cash is not legally property, raising new questions fo...Priority Gold | SponsoredThe 2026 beginners Guide to Gold IRAsGold trades near record highs while silver just topped $81 an ounce for the first time ever. Thousands of A...Goldco Direct, LLC | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredThe $8,000 Gold Call Every Retirement Saver Needs to Read Right NowGold didn't creep higher—it broke $5,000, a level many analysts thought would hold. Now JPMorgan, the biggest ...Golden Crest Metals | SponsoredElon's Terrifying Warning: America Is "1,000% Going Bankrupt"The national debt just crossed $39 trillion, and Elon Musk - former head of the Department of Government Effic...American Hartford Gold | SponsoredThis sub-5 dollar stock operates next to SpaceX and Blue OriginA small public company trading under $5 a share operates inside the secure perimeter of Kennedy Space Center, ...Freedom Financial | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImageneBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImageneBio With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
